Abstract
The deregulated cell cycle is a prominent hallmark of oncogenesis. In addition to the genetic alterations in G1 and S phase, emerging data demonstrate that the loss of checkpoint control at the G2/M transition is also closely involved in neoplastic transformation. Among many modulators of the G2/M transition, the defective regulation of cyclin B1, the regulatory subunit of cyclin dependent kinase 1 (Cdk1), and of Polo-like kinase 1 (Plk1) is attracting increasing attention as both of them are overexpressed in a wide spectrum of human tumors. Cyclin B1 and Plk1 serve as negative prognostic markers for patients with various tumors. In this review, we focus on these two molecules and highlight their roles in normal cell cycle, the involvement in oncogenesis and their potential as intervention targets for antitumor therapy.
Keywords: g/m transition, polo-like kinase, cdk/cyclin b, inhibition of proliferation, apoptosis
Letters in Drug Design & Discovery
Title: Targeting the G2/M Transition for Antitumor Therapy
Volume: 2 Issue: 4
Author(s): J. Yuan and K. Strebhardt
Affiliation:
Keywords: g/m transition, polo-like kinase, cdk/cyclin b, inhibition of proliferation, apoptosis
Abstract: The deregulated cell cycle is a prominent hallmark of oncogenesis. In addition to the genetic alterations in G1 and S phase, emerging data demonstrate that the loss of checkpoint control at the G2/M transition is also closely involved in neoplastic transformation. Among many modulators of the G2/M transition, the defective regulation of cyclin B1, the regulatory subunit of cyclin dependent kinase 1 (Cdk1), and of Polo-like kinase 1 (Plk1) is attracting increasing attention as both of them are overexpressed in a wide spectrum of human tumors. Cyclin B1 and Plk1 serve as negative prognostic markers for patients with various tumors. In this review, we focus on these two molecules and highlight their roles in normal cell cycle, the involvement in oncogenesis and their potential as intervention targets for antitumor therapy.
Export Options
About this article
Cite this article as:
Yuan J. and Strebhardt K., Targeting the G2/M Transition for Antitumor Therapy, Letters in Drug Design & Discovery 2005; 2 (4) . https://dx.doi.org/10.2174/1570180054038378
DOI https://dx.doi.org/10.2174/1570180054038378 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
Anti-Cancer Agents in Medicinal Chemistry Isolation, Purification, Characterisation and Application of L-ASNase: A Review
Recent Patents on Biotechnology Drug-Membrane Interactions: Significance for Medicinal Chemistry
Current Medicinal Chemistry Novel Action and Mechanism of Auranofin in Inhibition of Vascular Endothelial Growth Factor Receptor-3-Dependent Lymphangiogenesis
Anti-Cancer Agents in Medicinal Chemistry Aminopeptidases of Malaria Parasites: New Targets for Chemotherapy
Infectious Disorders - Drug Targets Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Treatment of Relapsed Acute Myeloid Leukaemia
Reviews on Recent Clinical Trials Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Protective Effect of Heat Shock Proteins in the Nervous System
Current Neurovascular Research Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry